Affinity DataKi: 0.0100nMAssay Description:Binding affinity to human integrin alphaVbeta6 assessed as dissociation constant up to 48 hrs by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0251nMAssay Description:Binding affinity to human integrin alphaVbeta6 assessed as dissociation constant up to 48 hrs by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 0.0316nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0398nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0398nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0398nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0398nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0398nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0501nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0631nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0631nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0631nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0631nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0794nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0794nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0794nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:Binding affinity to alphaVbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.107nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.174nMAssay Description:Inhibition of integrin alphavbeta6 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-1(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Inhibition of integrin alphavbeta1 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
Affinity DataKi: 2nMAssay Description:Binding affinity to human integrin alphaVbeta6 assessed as dissociation constant up to 48 hrs by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 5.01nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 5.01nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 6.31nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 6.31nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Rattus norvegicus)
University Of Strathclyde
Curated by ChEMBL
University Of Strathclyde
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Inhibition of rat ATX by Michaelis-Menten analysisMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Inhibition of integrin alphavbeta5 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 12.6nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 15.8nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Rattus norvegicus)
University Of Strathclyde
Curated by ChEMBL
University Of Strathclyde
Curated by ChEMBL
Affinity DataKi: 24nMAssay Description:Inhibition of rat ATX by Michaelis-Menten analysisMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 25nMAssay Description:Displacement of [125I]CCK8S from human CCK2RMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 25nMAssay Description:Displacement of [125I]CCK-8S from CCK2 receptorMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 25.1nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-2R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 32nMAssay Description:Displacement of [125I]CCK8S from human CCK2RMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Displacement of [125I]CCK8S from human CCK2RMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of integrin alphavbeta3 (unknown origin) by radioligand binding assayMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 63nMAssay Description:Displacement of [125I]CCK8S from human CCK2RMore data for this Ligand-Target Pair
TargetGastrin/cholecystokinin type B receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 79nMAssay Description:Displacement of [125I]CCK8S from human CCK2RMore data for this Ligand-Target Pair
TargetCholecystokinin receptor type A(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 100nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-1R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 100nMAssay Description:Inhibition of Trypanosoma cruzi cruzainMore data for this Ligand-Target Pair
Affinity DataKi: 110nMAssay Description:Inhibition of Trypanosoma cruzi cruzainMore data for this Ligand-Target Pair
TargetCholecystokinin receptor type A(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 126nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-1R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 130nMAssay Description:Inhibition of Trypanosoma cruzi cruzainMore data for this Ligand-Target Pair
TargetCholecystokinin receptor type A(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 158nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-1R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetCholecystokinin receptor type A(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 158nMAssay Description:Displacement of [125I]-CCK-8S from human CCK-1R after 100 mins by liquid scintillation countingMore data for this Ligand-Target Pair